The role of self-expanding vascular stent in superior vena cava syndrome for advanced tumours.
Adult
Aged
Aged, 80 and over
Carcinoma
/ complications
Endovascular Procedures
/ instrumentation
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Lung Neoplasms
/ complications
Lymphatic Metastasis
Lymphoma, Non-Hodgkin
/ complications
Male
Middle Aged
Retrospective Studies
Self Expandable Metallic Stents
Superior Vena Cava Syndrome
/ etiology
Treatment Outcome
Lung cancer
Non-Hodgkin’s lymphoma
Superior vena cava self-expanding stent
Superior vena cava syndrome
Journal
Annals of the Royal College of Surgeons of England
ISSN: 1478-7083
Titre abrégé: Ann R Coll Surg Engl
Pays: England
ID NLM: 7506860
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
pubmed:
9
3
2021
medline:
10
4
2021
entrez:
8
3
2021
Statut:
ppublish
Résumé
Superior vena cava (SVC) syndrome (SVCS) is a life-threatening occurrence that necessitates prompt treatment. At present, endovascular stenting is proposed as a first-line treatment to relieve symptoms. We assessed the effectiveness, safety and outcome of SVC stent positioning in patients affected with advanced cancer. Forty-two patients undergoing stent positioning in the SVC for neoplasms from January 2002 to December 2018 form the basis of this retrospective study. Demographic data, risk factors, associated diseases, symptoms at presentation according to the score proposed by Kishi and the type of SVCS according to Sanford and Doty were collected. Minor and major complications were recorded. Suspected stent occlusion was confirmed by means of recurrence of symptoms followed by a confirmatory computed tomography (CT). Thirty-four (81%) patients had a nonresectable lung tumour invading or compressing the SVC. Five (12%) patients had a non-Hodgkin's lymphoma, and three (7%) had metastatic lymphadenopathies. Nitinol stents (Memotherm We recommend the use of the endovascular procedure as a first-line treatment in locally advanced or metastatic tumour in the presence of SVCS.
Identifiants
pubmed: 33682470
doi: 10.1308/rcsann.2020.7127
pmc: PMC10335251
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
296-301Références
Bull Cancer Radiother. 1996;83(3):153-7
pubmed: 8977565
World Neurosurg. 2019 May;125:414-424
pubmed: 30822589
Am J Cardiol. 1985 Nov 1;56(12):829-30
pubmed: 2932906
Ann Vasc Surg. 2011 Aug;25(6):823-9
pubmed: 21620672
Eur J Vasc Endovasc Surg. 2017 Feb;53(2):238-254
pubmed: 28007450
Cardiovasc Intervent Radiol. 2006 May-Jun;29(3):319-22
pubmed: 16502166
Eur J Radiol. 2009 Aug;71(2):343-9
pubmed: 18554839
Chest. 1975 Jul;68(1):32-5
pubmed: 1149526
Cancer Treat Rev. 1985 Sep;12(3):209-18
pubmed: 3907828
J Infect. 2000 Mar;40(2):187-9
pubmed: 10841098
Int Angiol. 2014 Dec;33(6):530-9
pubmed: 25491403
Radiology. 1993 Nov;189(2):531-5
pubmed: 8210386
Eur J Cardiothorac Surg. 2000 Apr;17(4):384-8
pubmed: 10773559
N Engl J Med. 2007 May 3;356(18):1862-9
pubmed: 17476012
N Engl J Med. 1980 Jan 3;302(1):61
pubmed: 6243166
Int Wound J. 2019 Jun;16(3):716-723
pubmed: 30773823
Eur Radiol. 2003 Apr;13(4):853-62
pubmed: 12664126
N J Med. 1995 Apr;92(4):245-8
pubmed: 7746518
Biomolecules. 2020 Jan 17;10(1):
pubmed: 31963569
Ann Thorac Surg. 1986 Feb;41(2):158-63
pubmed: 3947168
Clin Oncol (R Coll Radiol). 1997;9(2):83-9
pubmed: 9135892
Semin Oncol. 2000 Feb;27(1):90-3
pubmed: 10697025
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Emerg Med Clin North Am. 2009 May;27(2):243-55
pubmed: 19447309
Radiology. 1968 Oct;91(4):713-8
pubmed: 4971126
Tech Vasc Interv Radiol. 2018 Jun;21(2):113-116
pubmed: 29784119
Radiology. 1986 Nov;161(2):295-8
pubmed: 3763891
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131